(CercleFinance.com) – The European Medicines Agency announced on Friday that its Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion on a new indication for Lynparza, AstraZeneca’s cancer drug.
The CHMP recommended the authorization of the drug in the treatment of patients with early breast cancer at risk called ‘HER2-negative’ and with BRCA1 and BRCA2 mutations, who have already undergone chemotherapy.
Lynparza, an oral drug, is already approved in the European Union for several types of tumours, ranging from ovarian cancer to prostate cancer.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.